Esperion Therapeutics, Inc. financial statements, including revenue, expenses, profit, and loss
The total revenue of ESPR for the last quarter is 32.25 M USD, and it's 5.06% lower compared to the previous quarter. The net income of Q4 23 is -56.34 M USD.